 BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. Nasdaq: BCTX, BCTXW TSX-V:BCT BriaCell or the Company, a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company the Shareholders for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 the Meeting. A total of 1,685,180 common shares of the Company the Common Shares were voted, representing 22.36 of the Companys issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following: 